Listen

Description

In this episode of Selling Signals, we're joined by Doug Garber, former PM at Millennium and analyst at Citadel, and Michelle Yang, who previously founded and developed the Consumer & Healthcare data team at Woodline, having also worked at Point72.

Together, they explain how investment teams work with data scientists and what happens when a new dataset enters the evaluation process. We discuss how funds prioritise competing data trials and why a product that looks promising can still struggle to secure a licence.

Michelle shares what vendors can do to make the evaluation process easier, including why responding quickly to technical questions can make an enormous difference. Doug provides the PM's perspective on what makes alternative data worth paying for and how it needs to fit into an investment workflow.

We finish by exploring what makes data products sticky and why funds ultimately choose to renew or replace them.